Journal article
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
Abstract
AIMS: In the Ongoing Telmisartan Alone and in Combination with Ramipril Trial (ONTARGET), dual agent renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting-enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) did not reduce the risk of renal and cardiovascular outcomes compared with the single use of either agent. Dual therapy however increased the incidence of hyperkalemia. We examined risk factors for …
Authors
Heerspink HJL; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Journal
European Journal of Preventive Cardiology, Vol. 21, No. 3, pp. 299–309
Publisher
Oxford University Press (OUP)
Publication Date
March 2014
DOI
10.1177/2047487313510678
ISSN
2047-4873
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzimidazolesBenzoatesBlood PressureCreatinineDrug Therapy, CombinationFemaleHeart FailureHospitalizationHumansHyperkalemiaHypertensionHypokalemiaKidneyKidney DiseasesLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionNonlinear DynamicsOdds RatioPotassiumProportional Hazards ModelsRamiprilRenal DialysisRenin-Angiotensin SystemRisk AssessmentRisk FactorsStrokeTelmisartanTime FactorsTreatment Outcome